Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 08.06.2026 2 Cancer 1 Cancer Lett 1 Clin Cancer Res 1 Eur Radiol 1 Eur Urol 1 Int J Urol 3 J Nucl Med 1 Lancet Oncol 4 N Engl J Med 2 Oncogene 1 PLoS Comput Biol 1 PLoS Genet 1 PLoS One 1 Radiology 1 Ther Adv Urol 2 Urol Int 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Cancer

1. LAWRENCE L
   Study adds new evidence on use of salvage focal therapy for radio-recurrent prostate cancer.
   Cancer. 2026;132:e70404.
   PubMed        
   
   
2. MARULANDA-CORZO V, Coraci S, Kakkar P, Okobi TJ, et al
   Top advances of the year: Radiopharmaceutical therapy for prostate cancer.
   Cancer. 2026;132:e70470.
   PubMed         Abstract available
   
   

   
   Cancer Lett

3. KRISHNA M, Garg P, Horne D, Salgia R, et al
   Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NFkappaB, JAK/STAT3, and epigenetic remodeling in castration-resistant disease.
   Cancer Lett. 2026;655:218647.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

4. SMORAGIEWICZ M, Bernard-Tessier A, Linch M, Shen J, et al
   Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.
   Clin Cancer Res. 2026 Jun 2. doi: 10.1158/1078-0432.CCR-26-0253.
   PubMed         Abstract available
   
   

   
   Eur Radiol

5. AGROTIS G, Thimansson E, Schoots IG
   Reference standards in AI-assisted MRI readings in prostate cancer screening: primetime for benchmarking.
   Eur Radiol. 2026 Jun 3. doi: 10.1007/s00330-026-12657.
   PubMed        
   
   

   
   Eur Urol

6. DING G, Wang J, Wu J
   Re: Khan S, Papa N, Kneebone A, et al. Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial). Eur Urol. In press. ht
   Eur Urol. 2026 Jun 3:S0302-2838(26)02164-0. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   

   
   Int J Urol

7. SUZUKI T, Fukuda T, Nishizaki K, Fukui K, et al
   Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.
   Int J Urol. 2026;33:e70533.
   PubMed         Abstract available
   
   

   
   J Nucl Med

8. PAULE A, Masson S, Rose Dite Modestine J, Kara N, et al
   Role of (18)F-PSMA PET/MRI in Prostate Cancer Recurrence After Prostatectomy.
   J Nucl Med. 2026 Jun 4:jnumed.126.272126. doi: 10.2967/jnumed.126.272126.
   PubMed         Abstract available
   
   
9. JIA KY, Kuten J, Jia HY, Bent EH, et al
   Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing (68)Ga-PSMA PET/CT.
   J Nucl Med. 2026 Jun 4:jnumed.126.272009. doi: 10.2967/jnumed.126.272009.
   PubMed         Abstract available
   
   
10. KASSAS M, Jaafari A, Shagera QA, Devriendt L, et al
    SPECT Versus PET for [(177)Lu]Lu-PSMA Response Assessment Using Quantitative RECIP 1.0.
    J Nucl Med. 2026 Mar 12:jnumed.125.271755. doi: 10.2967/jnumed.125.271755.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

11. DEWEESE TL, Manzanera A, Sylvester J, Wheeler T, et al
    Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet Oncol. 2026;27:673-685.
    PubMed         Abstract available
    
    

    
    N Engl J Med

12. AGARWAL N, Matsubara N, Azad AA, Saad F, et al
    PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
    N Engl J Med. 2026 May 30. doi: 10.1056/NEJMoa2604126.
    PubMed         Abstract available
    
    
13. ANTONARAKIS ES
    A Watershed Moment in the Perioperative Treatment of Prostate Cancer.
    N Engl J Med. 2026 May 31. doi: 10.1056/NEJMe2606250.
    PubMed        
    
    
14. MCKAY RR
    Precision Intensification in Metastatic Prostate Cancer.
    N Engl J Med. 2026 May 30. doi: 10.1056/NEJMe2605582.
    PubMed        
    
    
15. TAPLIN ME, Gleave M, Shore ND, Lopez-Gitlitz A, et al
    Perioperative Apalutamide in High-Risk Localized Prostate Cancer.
    N Engl J Med. 2026 May 31. doi: 10.1056/NEJMoa2603878.
    PubMed         Abstract available
    
    

    
    Oncogene

16. LI S, Kang Y, Guan Y, Li J, et al
    Specifically targeted engineered exosomes loaded with circAKR1A1 enhance tumorigenesis and metastasis in prostate cancer by activating the PI3K/Akt signalling pathway.
    Oncogene. 2026 May 30. doi: 10.1038/s41388-026-03833.
    PubMed         Abstract available
    
    
17. LUO M, Wu C, Zhou M, Liu R, et al
    Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1.
    Oncogene. 2026 May 30. doi: 10.1038/s41388-026-03828.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

18. HESS JM, Dzeng RK, Ilies I, Schapiro D, et al
    MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.
    PLoS Comput Biol. 2026;22:e1014274.
    PubMed         Abstract available
    
    

    
    PLoS Genet

19. ZHANG H, He K, Tsoi LC, Zhou X, et al
    mFABIO: An integrative multi-tissue TWAS fine-mapping approach to prioritize potentially causal genes and tissues underlying binary traits.
    PLoS Genet. 2026;22:e1012157.
    PubMed         Abstract available
    
    

    
    PLoS One

20. ZHU X, Wu Q, Li Y, Liu Z, et al
    Integrating network toxicology, machine learning, and single-cell sequencing to reveal the FASN-mediated role of phenolic endocrine disruptors in water in promoting prostate cancer.
    PLoS One. 2026;21:e0350638.
    PubMed         Abstract available
    
    

    
    Radiology

21. DE BIE KCC, Cornud FC, Walser EM, van Riel LAMJG, et al
    One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study.
    Radiology. 2026;319:e251658.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

22. MOISANDER M, Holsa O, Teittinen K, Kysenius K, et al
    Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014-2022 in Pirkanmaa, Finland-an observational study.
    Ther Adv Urol. 2026;18:17562872261451289.
    PubMed         Abstract available
    
    

    
    Urol Int

23. BEHNEL N, Engelage L, Lumiani A, Buchner A, et al
    Transition Zone PSA Density Does Not Improve Detection of Clinically Significant Prostate Cancer Over Whole-Gland PSAD: A Volume-Stratified Analysis in 3,958 Patients.
    Urol Int. 2026 Jun 4:1-15. doi: 10.1159/000552900.
    PubMed         Abstract available
    
    
24. ALBARGHOUTH MH, Leeder M, Leucht K, Seifert P, et al
    Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate and High-Risk Prostate Cancer.
    Urol Int. 2026 Jun 4:1-14. doi: 10.1159/000552672.
    PubMed         Abstract available
    
    

    
    Urology

25. LEPOR H, Fiske J, Tafa M, Pirraglia E, et al
    Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.
    Urology. 2026 Jun 1:S0090-4295(26)00343-2. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum